112 Hbd2 Inhibits HIV Via CCR6, a Receptor Expressed on Memory, Dendritic and Th17 Cells

Mark K. Lafferty,Lingling Sun,Wuyuan Lu,Alfredo Garzino-Demo
DOI: https://doi.org/10.1097/01.qai.0000351069.36343.fa
2009-01-01
Abstract:Human beta defensins (hBD) are antimicrobial peptides that are produced by epithelial cells, and are components of innate immunity in mucosae. hBD2 and 3 inhibit HIV infection. Based on the properties of these cationic peptides, which inhibit infectious agents by disrupting their negatively-charged membranes or to glycan moieties on their glycoproteins we expected that hBD2 would exert its HIV-suppressive activity by inactivating HIV, binding to its envelope. While we observed some degree of virus inactivation, we found that hBD2 inhibits HIV also after virus entry. Since hBD2 binds to, and triggers signaling via the chemokine receptor CCR6, we tested the hypothesis that CCR6 mediates the antiviral activity of hBD2. Three lines of evidence support this hypothesis. First, MIP-3α (CCL20), the chemokine ligand for CCR6, induces antiviral activity. Second, hBD2 loses efficacy when tested in CCR6- cells, both in single cycle and spreading infectivity assays. Third, Bordetella Pertussis toxin, an inhibitor of chemokine receptor -mediated intracellular signaling, abrogates the antiviral activity of hBD2 and MIP-3α. Our mechanistic studies show that HIV inhibition occurs at an early stage, prior to completion of reverse transcription. In summary, this is a novel antiviral activity mediated by a chemokine receptor. CCR6 is expressed in cells that are highly relevant to HIV infection, mucosally and in the periphery: memory CCR5+ T lymphocytes, dendritic cells and, based on our data, on LPS-activated macrophages. Interestingly, CCR6 is one of the markers for the Th17 subset of T lymphocytes. Published reports have shown that CCR6+ and Th17 cells are specifically lost in the course of progressive HIV disease or in primate models of AIDS. Thus, a mechanism that protects CCR6 cells from infection may yield novel preventive or therapeutic approaches to HIV infection.
What problem does this paper attempt to address?